

Machine Learning in MedTech


Glaucoma Prognostication Platform

Aristotelis Agianniotis, PhD EPFL
Senior academic associate, HES-SO VS

31.01.2017

Applied Machine Learning Days - SwissTech Convention Center, EPFL

To put you in context...



- Contact lens embedding a micro-sensor. (1)
- Antenna receives wirelessly the info from the contact lens. (2)
- Data transmitted to portable recorder. (3)
- Data stored locally in portable recorder during the session. (4) Later transferred to the software.

What kind of data?

- Continuous measurements
- 30s of measurements every 5min for 24h
- Metadata anonymized (e.g., health status, glaucoma type, glaucoma speed progression, others)
- More than 2000 individuals in total




Why and How


- Why?
 - 80 million people worldwide suffer from glaucoma leading to blindness
 - Intraocular pressure follows individual nycthemeral patterns
 - Need for continuous monitoring
 - Help medical doctors in decision making
- How?
 - Provide a **machine learning platform** for 24h profiles of ocular dimensional changes to predict the **progression of glaucoma.**

What


- From business needs formulate machine learning problems
- Data preparation, outliers management, etc.
- Features definition and extraction
- Dimension reduction
- Leading parameters in a profile
- Pattern recognition
- Supervised learning
 - Prediction of glaucoma visual field loss / glaucoma progression
 - Classification of different states of glaucoma
- Unsupervised learning
 - Clustering curves to glaucoma varieties



Example of curve comparison:
Two 24 hour profiles of the same patient before and one month after treatment.



n1 échantillons de la classe 1
 n2 échantillons de la classe 2
 Taille t de chaque classe du set de test :
 $t = 0.25 * \min(n1, n2)$



Sélection aléatoire de t échantillons de classe 1 et t échantillons de classe 2 pour faire le set de test de cette itération. Les échantillons restants vont dans le set d'entraînement.

Sélection des caractéristiques et optimisation des hyper paramètres du modèle sur le **set d'entraînement uniquement**.

Si le set d'entraînement n'est pas équilibré, répliquer les éléments du set le plus petit pour arriver à la parité.

Entraînement du modèle sur tout le set d'entraînement en utilisant les meilleurs hyper paramètres et les meilleures caractéristiques.

Test du modèle sur le set de test.

Résultat : AUC sur le set de test



100 itérations

Distribution d'AUC



Calcul de la distribution des 100 AUC. La moyenne et l'intervalle de confiance correspondent au **score final**.

Principal Component Analysis, Dynamic Time Warping, clustering methods (K-Means, Agglomerative, Birch, Gaussian Mixture Models), Symbolic Aggregate Approximation, feature selection based on Random Forest and Gaussian Mixture Models, classification methods (Random Forest, Support Vector Machine), regression (linear model, K-Nearest Neighbors, Kernel Ridge Regression, Support Vector Regression)



Slow vs. Fast

Initial dataset

- POAG + Horus
- Size : 142
- dB range - inf. to + 2 dB

According to manufacturer

- Normal + 2 dB to - 2 dB
- Early - 2 dB to - 6 dB
- Moderate - 6 dB to - 12 dB
- Advanced - 12 dB to - inf.

| ProgressionEnd ProgressionStart | Normal | Early | Moderate | Advanced | |
|------------------------------------|--------|-------|----------|----------|-------|
| Normal | 5 | 9 | 10 | 14 | Fast? |
| Early | 2 | 10 | 3 | 15 | |
| Moderate | 10 | 17 | 2 | 7 | Slow? |
| Advanced | 28 | 8 | 0 | 2 | |
| | 65 | 19 | 58 | | |

Added value

- Better understanding of glaucoma disease and glaucoma progression (visual field loss)
- New business opportunities
- Medical doctors increased interest and involvement
- Clinical trials to come
- FDA De Novo (Diurnal Pattern Recorder System)

Partners



Schweizerische Eidgenossenschaft
Confédération suisse
Confederazione Svizzera
Confederaziun svizra
Commission pour la technologie et
l'innovation CTI

SENSIMED



innovation in medical micro-technology

Contact info <https://ch.linkedin.com/in/aristotelisagianniotis>